文献速递白血病造血干细胞移植与细胞治疗

Pegaspargase修正的风险导向方案治疗成人急性淋巴细胞白血病:GIMEMA LAL1913试验结果

Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial.
PubMed 文献 · Blood Adv · 2023-01-01

LAL1913试验在203例18-65岁费城染色体阴性急性淋巴细胞白血病/淋巴瘤患者中,于8个疗程方案的第1、2、5、6疗程加入pegaspargase 2000 IU/m2,>55岁者减量,并按临床特征和微小残留病风险分层决定异基因造血细胞移植或维持治疗;完全缓解率91%,3年总生存率66.7%,达到主要终点。

要点

  • 203例患者完全缓解率91%,3年总生存率66.7%、无事件生存率57.7%、无病生存率63.3%。
  • 符合移植条件者中,移植组无病生存率70% vs 未移植组26%(P <.0001)。
  • 年龄和微小残留病为独立预后因素,年龄>40岁且MRD阳性者无病生存率25%。

核心结论

  • 该方案在多中心全国性背景下改善了65岁及以下费城染色体阴性急性淋巴细胞白血病/淋巴瘤患者的结局。

研究设计与样本

  • GIMEMA LAL1913为多中心全国性试验,纳入203例18至65岁费城染色体阴性急性淋巴细胞白血病/淋巴瘤患者,中位年龄39.8岁。
  • 在8个疗程方案的第1、2、5、6疗程加入pegaspargase 2000 IU/m2,>55岁患者减量。
  • 缓解者按临床特征和微小残留病进行风险分层,决定异基因造血细胞移植或维持治疗。

主要发现

  • 203例患者中91%达到完全缓解。
  • 3年总生存率66.7%、无事件生存率57.7%、无病生存率63.3%,达到2年无病生存率>55%的主要研究终点。
  • 按意向治疗,化疗分配队列(n = 94)无病生存率74%,移植分配队列(n = 91)无病生存率50%。
  • 时间依赖分析显示,符合条件患者中移植组无病生存率70% vs 未移植组26%(P <.0001)。
  • 多因素分析中,年龄和微小残留病为独立预测无病生存率的因素:年龄≤40岁且MRD阴性者86%,MRD阳性或年龄>40岁者64%-65%,年龄>40岁且MRD阳性者25%(P < .0001)。

关键数值与推荐

  • pegaspargase 2000 IU/m2用于第1、2、5、6疗程,>55岁患者减量。
  • 主要研究终点为2年无病生存率>55%,实际达到。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pediatric-inspired chemotherapy is the standard of care for younger adults with Philadelphia chromosome-negative acute lymphoblastic leukemia/lymphoma (Ph- ALL/LL). In LAL1913 trial, the Gruppo Italiano Malattie EMatologiche dell'Adulto added pegaspargase 2000 IU/m2 to courses 1, 2, 5, and 6 of an 8-block protocol for patients aged from 18 to 65 years, with dose reductions in patients aged >55 years. Responders were risk stratified for allogeneic hematopoietic cell transplantation (HCT) or maintenance per clinical characteristics and minimal residual disease (MRD). Of 203 study patients (median age, 39.8 years), 91% achieved a complete remission. The 3-year overall survival, event-free, and disease-free survival (DFS) rates were 66.7%, 57.7%, and 63.3%, respectively, fulfilling the primary study end point of a 2-year DFS >55%. Although based on the intention-to-treat, the DFS being 74% and 50% in the chemotherapy (n = 94) and HCT (n = 91) assignment cohorts, respectively, a time-dependent analysis proved the value of HCT in patients who were eligible (DFS HCT 70% vs no HCT 26%; P <.0001). In multivariate analysis, age and MRD were independent factors predicting DFS rates of 86% (age ≤ 40 and MRD-negative), 64%-65% (MRD-positive or age > 40) and 25% (age > 40 and MRD-positive); P < .0001. Grade ≥2 pegaspargase toxicity was mainly observed at course 1, contributing to induction death in 2 patients but was rare thereafter. This program improved outcomes of patients with Ph- ALL/LL aged up to 65 years in a multicenter national setting. This trial was registered at www.clinicaltrials.gov as #NCT02067143.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Bassan R, Chiaretti S, Della Starza I, et al. Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial. Blood Adv. 2023. PMID: 37276451. doi:10.1182/bloodadvances.2022009596

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。